Abstract
Despite substantial advancements have been achieved in the identification of long noncoding RNA (lncRNA) molecules, many challenges still remain into their functional characterization. Loss-of-function approaches are needed to study oncogenic lncRNAs, which appear more difficult to knock down by RNA interference as compared to mRNAs. In this chapter, we present a protocol based on the use of a novel class of antisense oligonucleotides, named locked nucleic acid (LNA) GapmeRs, to inhibit the oncogenic lncRNA NEAT1 in multiple myeloma cells. Overall, this approach holds many advantages, including its possible independence from delivery reagents as well as the capability to knock down lncRNAs even in hard-to-transfect suspension cells, like hematopoietic cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10(3):155–159. https://doi.org/10.1038/nrg2521
Amodio N, Raimondi L, Juli G et al (2018) MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. J Hematol Oncol 11(1):63. https://doi.org/10.1186/s13045-018-0606-4
Kopp F, Mendell JT (2018) Functional classification and experimental dissection of long noncoding RNAs. Cell 172(3):393–407. https://doi.org/10.1016/j.cell.2018.01.011
Slack FJ, Chinnaiyan AM (2019) The role of non-coding RNAs in oncology. Cell 179(5):1033–1055. https://doi.org/10.1016/j.cell.2019.10.017
Arun G, Diermeier SD, Spector DL (2018) Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med 24(3):257–277. https://doi.org/10.1016/j.molmed.2018.01.001
Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5(4):381–391. https://doi.org/10.1517/17425250902877680
Geary RS, Norris D, Yu R et al (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46–51. https://doi.org/10.1016/j.addr.2015.01.008
Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46(4):1584–1600. https://doi.org/10.1093/nar/gkx1239
Lundin KE, Hojland T, Hansen BR et al (2013) Biological activity and biotechnological aspects of locked nucleic acids. Adv Genet 82:47–107. https://doi.org/10.1016/B978-0-12-407676-1.00002-0
Hagedorn PH, Persson R, Funder ED et al (2018) Locked nucleic acid: modality, diversity, and drug discovery. Drug Discov Today 23(1):101–114. https://doi.org/10.1016/j.drudis.2017.09.018
Amodio N, D’Aquila P, Passarino G et al (2017) Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. Expert Opin Ther Targets 21(1):91–101. https://doi.org/10.1080/14728222.2016.1266339
Janssen HL, Kauppinen S, Hodges MR (2013) HCV infection and miravirsen. N Engl J Med 369(9):878. https://doi.org/10.1056/NEJMc1307787
Kurreck J, Wyszko E, Gillen C et al (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 30(9):1911–1918. https://doi.org/10.1093/nar/30.9.1911
Wahlestedt C, Salmi P, Good L et al (2000) Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A 97(10):5633–5638. https://doi.org/10.1073/pnas.97.10.5633
Stein CA, Hansen JB, Lai J et al (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 38(1):e3. https://doi.org/10.1093/nar/gkp841
Amodio N, Stamato MA, Juli G et al (2018) Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia 32(9):1948–1957. https://doi.org/10.1038/s41375-018-0067-3
Morelli E, Biamonte L, Federico C et al (2018) Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. Blood 132(10):1050–1063. https://doi.org/10.1182/blood-2018-03-836601
Ronchetti D, Todoerti K, Vinci C et al (2020) Expression pattern and biological significance of the lncRNA ST3GAL6-AS1 in multiple myeloma. Cancers (Basel) 12(4):782. https://doi.org/10.3390/cancers12040782
Taiana E, Favasuli V, Ronchetti D et al (2020) Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia 34(1):234–244. https://doi.org/10.1038/s41375-019-0542-5
Zhang Y, Qu Z, Kim S et al (2011) Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther 18(4):326–333. https://doi.org/10.1038/gt.2010.133
Roux BT, Lindsay MA, Heward JA (2017) Knockdown of nuclear-located enhancer RNAs and long ncRNAs using locked nucleic acid GapmeRs. Methods Mol Biol 1468:11–18. https://doi.org/10.1007/978-1-4939-4035-6_2
Acknowledgments
This work was financially supported by grants to Antonino Neri [from Associazione Italiana Ricerca sul Cancro (AIRC) (IG16722, IG24365, and the “Special Program Molecular Clinical Oncology-5 per mille” #9980, 2010/15)]; to Pierfrancesco Tassone (from AIRC, IG21588); to Nicola Amodio [from Italian Ministry of Health (GR-2016-02361523) and from AIRC (IG24449)].
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Taiana, E. et al. (2021). In Vitro Silencing of lncRNAs Using LNA GapmeRs. In: Navarro, A. (eds) Long Non-Coding RNAs in Cancer. Methods in Molecular Biology, vol 2348. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1581-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1581-2_10
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1580-5
Online ISBN: 978-1-0716-1581-2
eBook Packages: Springer Protocols